In the original article, there was an error \[wrong description on LY3164530 (Eli Lilly) antibody in the last paragraph of page 9 of original article\]. 

A correction has been made to section "HETERODIMERIC Fc-BASED ANTIBODIES IN DIVERSE FORMATS", subsection "Intact IgG Formats with Correct LC Association", sixth Paragraph (line 8--12 of the sixth paragraph) (In the last paragraph of page 9 of original article):

An alternative approach for enforcing correct HC~VH-CH1~--LC association includes introduction of a set of mutations at the heterodimeric VL--CL and VH--CH1 interface (18, 66, 67), similar to modification of the CH3 interface for the heterodimeric Fc design.  In an ortho-Fab IgG approach (18), structure-based regional design introduced complementary mutations at the LC and HC~VH-CH1~ interface in only one Fab, without any changes being made to the other Fab (Figure 3).  Zymeworks is currently developing intact IgG-format bsAbs generated by the combination of ortho-Fab IgG and ZW1 Fc technologies (<http://www.zymeworks.com/>). 

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. 

Conflict of Interest Statement {#S1}
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. 

[^1]: Edited and Reviewed by: Tianlei Ying, Fudan University, China

[^2]: Specialty section: This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
